Published in Int J Clin Oncol on December 18, 2016
Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies. BMC Med Res Methodol (2006) 3.78
Diagnostic value of carcinoembryonic antigen in malignant pleural effusion: a meta-analysis. Respirology (2008) 1.17
Diagnosis and treatment of malignant pleural effusion: a systematic literature review and new approaches. Am J Clin Oncol (2010) 1.13
Survival of lung adenocarcinoma patients with malignant pleural effusion. Eur Respir J (2012) 1.03
Malignant pleural effusions: a review. Clin Chest Med (2013) 1.01
Prognostic impact of serum CYFRA 21-1 in patients with advanced lung adenocarcinoma: a retrospective study. BMC Cancer (2013) 1.00
Downregulation of cell-free miR-198 as a diagnostic biomarker for lung adenocarcinoma-associated malignant pleural effusion. Int J Cancer (2013) 1.00
Diagnostic value of serum carbohydrate antigen 19-9 in pancreatic cancer: a meta-analysis. Tumour Biol (2014) 0.97
Diagnosis of pleural effusions. Experience with clinical studies, 1986 to 1990. Chest (1995) 0.96
Pleural involvement in lung cancer. J Thorac Dis (2015) 0.94
CEA, AFP, CA125, CA153 and CA199 in malignant pleural effusions predict the cause. Asian Pac J Cancer Prev (2014) 0.92
Diagnostic value of tumor markers in lung adenocarcinoma-associated cytologically negative pleural effusions. Cancer Cytopathol (2013) 0.90
The new IASLC/ATS/ERS lung adenocarcinoma classification from a clinical perspective: current concepts and future prospects. J Thorac Dis (2014) 0.88
Diagnostic accuracy of Cyfra 21-1 for head and neck squamous cell carcinoma: a meta-analysis. Eur Rev Med Pharmacol Sci (2013) 0.88
Diagnostic value of tumor antigens in malignant pleural effusion: a meta-analysis. Transl Res (2015) 0.87
Prognostic factors affecting survival in non-small cell lung carcinoma patients with malignant pleural effusions. Clin Respir J (2015) 0.87
Diagnostic Value of Circulating Extracellular miR-134, miR-185, and miR-22 Levels in Lung Adenocarcinoma-Associated Malignant Pleural Effusion. Cancer Res Treat (2014) 0.84
Diagnostic value of Her-2/neu, Cyfra 21-1, and carcinoembryonic antigen levels in malignant pleural effusions of lung adenocarcinoma. Pathology (2010) 0.84
Immunocytochemical panel for distinguishing carcinoma cells from reactive mesothelial cells in pleural effusions. Cytopathology (2008) 0.83
Diagnostic and predictive role of cell-free midkine in malignant pleural effusions. J Cancer Res Clin Oncol (2012) 0.83
Pleural fluid tumour markers in malignant pleural effusion with inconclusive cytologic results. Curr Oncol (2015) 0.82
The 2011 IASLC/ATS/ERS pulmonary adenocarcinoma classification: a landmark in personalized medicine for lung cancer management. J Thorac Dis (2014) 0.81
The diagnostic value of apolipoprotein E in malignant pleural effusion associated with non-small cell lung cancer. Clin Chim Acta (2013) 0.80
Prognostic value of aberrant hypermethylation in pleural effusion of lung adenocarcinoma. Cancer Biol Ther (2012) 0.80
Accuracy of the Bronchoalveolar Lavage Enzyme-Linked Immunospot Assay for the Diagnosis of Pulmonary Tuberculosis: A Meta-analysis. Medicine (Baltimore) (2016) 0.78
TTF-1 and napsin A on cell blocks and supernatants of pleural fluids for labeling malignant effusions. Respirology (2015) 0.78
Diagnostic performance of CD66c in lung adenocarcinoma-associated malignant pleural effusion: comparison with CEA, CA 19-9, and CYFRA 21-1. Pathology (2015) 0.78